All articles tagged with #chikungunya virus
Chikungunya virus is rapidly spreading across Chinese cities and has been reported in multiple countries worldwide. It is transmitted by mosquitoes, causing symptoms like fever and joint pain, but is not highly fatal. China is implementing strict measures, including quarantine and mosquito control, to contain the outbreak, which has affected thousands in China and is part of a broader global spread.
A significant outbreak of the chikungunya virus has occurred in Guangdong, China, with nearly 3,000 cases reported in a week, prompting strict measures including mosquito control and quarantine efforts, as authorities aim to contain the mosquito-borne disease.
The FDA has granted approval for the first vaccine against the chikungunya virus, a disease primarily transmitted through mosquito bites. The vaccine, Ixchiq, is intended for individuals aged 18 and older who are at a higher risk of exposure to the virus. Chikungunya virus poses a global health threat, with millions of cases reported in the past 15 years. While the highest risk is in tropical and subtropical regions, the virus has spread to other areas. Symptoms include fever, joint pain, rash, and headache. The vaccine, which contains a weakened version of the virus, was evaluated in clinical studies and showed common side effects such as headache and muscle pain. Researchers will conduct a postmarket study to assess potential risks.
The US Food and Drug Administration has approved the first vaccine, Ixchiq, to prevent disease caused by the chikungunya virus. Chikungunya is a mosquito-borne disease that can be debilitating and even deadly, particularly for newborns. The vaccine, made by Valneva Austria GmbH, is a single-dose vaccine approved for adults at an increased risk of exposure to the virus. Chikungunya has become an emerging threat to global health, with millions of cases in the past 15 years. The vaccine contains a live, weakened version of the virus and may cause symptoms similar to an infection. The FDA is requiring a postmarket study to ensure there are no serious risks associated with the vaccine.
A study has found that the Chikungunya virus can be transmitted between cells through intercellular extensions, both in laboratory settings and in living organisms. These extensions, which physically connect infected and uninfected cells, facilitate the spread of the virus. The findings provide insights into the mechanisms of Chikungunya virus transmission and could potentially inform the development of intervention strategies.